Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Portions of the resected primary pancreatic tumor were fixed in 10 per cent neutral formalin, Bouin's fluid, Zenker's formol, 2 per cent gluteraldehyde in cacodylate buffer at pH 7.2 and 1 per ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

“It came as a surprise that our approach works so well,” Lu said. In preclinical (non-human) studies, the vaccine completely ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

Stage 4 pancreatic cancer is the most advanced form of the disease, meaning it has spread beyond the pancreas to distant ...

I was told I wouldn’t live to see my daughters’ weddings — but 12 years later, I’ve been there for two, and I’m holding out ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...